{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000053","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-06-18T11:00:03+00:00","discovered_at":"2026-06-18T11:05:00.314963+00:00","generated_at":"2026-06-18T11:05:24.119323+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM","bullets":["Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.","981 patients enrolled; 25% did not initiate maintenance phase across both arms.","1-/2-/3-year survival rates: Early Start 70.9%/33.9%/22.5%; Maintenance 72.0%/31.6%/18.4%.","No new safety signals; TTFields with chemoradiation was well-tolerated.","Results accepted for presentation at ASTRO 2026 Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000053","json":"https://secwatch.observer/filing/0001645113-26-000053.json","markdown":"https://secwatch.observer/filing/0001645113-26-000053.md","text":"https://secwatch.observer/filing/0001645113-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/0001645113-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/nvcr-20260618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:05:24.119323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}